[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ligand Pharm (LGND)

Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,436,614
  • Shares Outstanding, K 20,038
  • Annual Sales, $ 268,090 K
  • Annual Income, $ 124,450 K
  • EBIT $ 74 M
  • EBITDA $ 104 M
  • 60-Month Beta 1.20
  • Price/Sales 15.72
  • Price/Cash Flow 26.79
  • Price/Book 4.23

Options Overview Details

View History
  • Implied Volatility 40.76% (+0.07%)
  • Historical Volatility 53.41%
  • IV Percentile 72%
  • IV Rank 26.67%
  • IV High 73.14% on 04/13/26
  • IV Low 28.98% on 08/08/25
  • Expected Move (DTE 5) 12.94 (5.84%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 152
  • Volume Avg (30-Day) 98
  • Put/Call OI Ratio 0.34
  • Today's Open Interest 1,436
  • Open Int (30-Day) 1,168
  • Expected Range 208.47 to 234.35

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $1.17
  • Number of Estimates 3
  • High Estimate $1.40
  • Low Estimate $1.05
  • Prior Year $0.24
  • Growth Rate Est. (year over year) +387.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
198.55 +11.51%
on 04/10/26
247.38 -10.50%
on 04/27/26
+13.32 (+6.40%)
since 04/08/26
3-Month
178.72 +23.89%
on 02/26/26
247.38 -10.50%
on 04/27/26
+30.97 (+16.26%)
since 02/06/26
52-Week
98.89 +123.90%
on 05/30/25
247.38 -10.50%
on 04/27/26
+118.90 (+115.99%)
since 05/08/25

Most Recent Stories

More News
Ligand Pharmaceuticals Q1 Earnings Call Highlights

Ligand Pharmaceuticals (NASDAQ:LGND) reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from key...

LGND : 221.41 (+5.27%)
Ligand: Q1 Earnings Snapshot

Ligand: Q1 Earnings Snapshot

LGND : 221.41 (+5.27%)
Ligand Reports First Quarter 2026 Financial Results

First quarter performance driven by strong year-over-year royalty revenue growth of  56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution...

LGND : 221.41 (+5.27%)
Can Ligand Pharmaceuticals Justify Its Valuation When the Royalty Growth Finally Slows?

Barchart Research What to Expect from LGND Earnings LGND Generated May 6, 2026 Current Price $231.11 EPS Estimate $$0.98 Consensus Rating Strong Buy Average Move 4.52% Can Ligand Pharmaceuticals Justify...

LGND : 221.41 (+5.27%)
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

$15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing total capital received from Ligand to $40 million to date in exchange for tiered royalty interest...

LGND : 221.41 (+5.27%)
MDT : 76.15 (-2.32%)
OBIO : 4.04 (+2.80%)
Ligand to Participate in May Investor Conferences

JUPITER, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor...

LGND : 221.41 (+5.27%)
XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of XOMA Royalty ...

XOMA : 41.89 (+1.45%)
LGND : 221.41 (+5.27%)
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

NEW YORK , April 27, 2026 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors concerning the...

LGND : 221.41 (+5.27%)
XOMA : 41.89 (+1.45%)
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator 

Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand’s long-term compounding growth, adding a complementary...

LGND : 221.41 (+5.27%)
XOMA : 41.89 (+1.45%)
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator

Transaction expands Ligand’s royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand’s long-term compounding growth, adding a complementary...

XOMA : 41.89 (+1.45%)
LGND : 221.41 (+5.27%)
XOMAP : 25.37 (+0.20%)
XOMAO : 25.30 (+0.22%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated...

See More

Key Turning Points

3rd Resistance Point 245.89
2nd Resistance Point 234.84
1st Resistance Point 228.12
Last Price 221.41
1st Support Level 210.36
2nd Support Level 199.31
3rd Support Level 192.59

See More

52-Week High 247.38
Last Price 221.41
Fibonacci 61.8% 190.66
Fibonacci 50% 173.14
Fibonacci 38.2% 155.61
52-Week Low 98.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.